[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postpartum-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postpartum-hemorrhage":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,56,83,109,135,165,197,217,242,262,284,313,336,363,387,412,435,458,490,511,539,561,586,610,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100643446","phase-4-carbetocin-monotherapy-versus-carbetocin-plus-oxytocin-infusion-in-elective-cesarean-delivery-a-non-inferiority-trial-100643446",false,"NCT07636421","Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial","Comparative Efficacy of Carbetocin Monotherapy Versus Carbetocin With Supplemental Oxytocin Infusion in Maintaining Uterine Tone and Preventing Blood Loss in Elective Cesarean Delivery: A Randomized, Double-Blind, Non-Inferiority Controlled Trial","CARBOXY-RCT","Inclusion Criteria:\n\n* Adult women aged 18 to 45 years\n* Scheduled for elective non-emergency cesarean delivery\n* Spinal anesthesia planned and administered as the sole anesthetic technique\n* Singleton pregnancy at gestational age of 37 completed weeks or more\n* ASA physical status II\n* Preoperative hemoglobin of 9 g\u002FdL or more\n* Able to provide written informed consent in Arabic or English\n\nExclusion Criteria:\n\n* Emergency or crash cesarean delivery\n* Placenta previa, placenta accreta spectrum disorder, or other abnormal placentation\n* Known uterine anomalies likely to impair contractility including fibroids greater than 5 cm, bicornuate or unicornuate uterus\n* Grand multiparity defined as 5 or more previous deliveries\n* Multiple gestation including twins or higher order\n* Polyhydramnios defined as amniotic fluid index greater than 24 cm\n* Prior oxytocin augmentation in current pregnancy for more than 6 hours\n* Known hypersensitivity to carbetocin, oxytocin, or any formulation excipient\n* Severe preeclampsia, eclampsia, or HELLP syndrome\n* Cardiovascular disease including arrhythmia, valvular disease, cardiomyopathy, or ischemic heart disease\n* Known coagulopathy or thrombocytopenia with platelets less than 100 x 10\\^9\u002FL\n* Hepatic or renal impairment\n* Body mass index greater than 40 kg\u002Fm2 at time of delivery\n* Enrollment in another interventional clinical trial","FEMALE","18 Years","45 Years",{"count":22,"type":23},332,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Background: Carbetocin is an established single-dose uterotonic agent for postpartum hemorrhage prophylaxis at elective cesarean delivery. Despite its proven efficacy, many clinicians routinely add a supplemental oxytocin infusion following carbetocin administration without evidence-based justification. Concurrent oxytocin receptor stimulation may be redundant, counterproductive through receptor desensitization, or incrementally beneficial - a mechanistic uncertainty that remains unresolved in the published literature.\n\nObjectives: To determine whether carbetocin monotherapy (100 micrograms IV bolus plus placebo infusion) is non-inferior to carbetocin plus supplemental oxytocin infusion (10 IU over 4 hours) in preventing the need for additional uterotonic agents within 24 hours of elective cesarean delivery.\n\nStudy Design: Prospective, randomized, double-blind, placebo-controlled, non-inferiority trial with an integrated pilot phase. Phase 1 (Pilot, n=60) establishes local feasibility and event rate. Phase 2 (Full trial, n=332) provides the definitive non-inferiority analysis.\n\nParticipants: Women aged 18-45 years undergoing elective cesarean delivery under spinal anesthesia at Qassim University Medical City, singleton pregnancy at or beyond 37 weeks, ASA physical status II, preoperative hemoglobin 9 g\u002FdL or more.\n\nInterventions: Group C (Monotherapy): Carbetocin 100 micrograms IV bolus plus placebo saline infusion 500 mL over 4 hours. Group C+O (Combination): Carbetocin 100 micrograms IV bolus plus oxytocin 10 IU in 500 mL saline over 4 hours.\n\nPrimary Outcome: Proportion of patients requiring at least one additional uterotonic agent within 24 hours of delivery.\n\nSecondary Outcomes: Quantitative intraoperative blood loss by gravimetric measurement; total 24-hour blood loss; actual blood loss by Gross formula; hemoglobin and hematocrit changes; uterine tone scores by verbal numerical rating scale (0-10) at 2, 5, and 10 minutes; incidence of postpartum hemorrhage; blood transfusion requirement; hemodynamic profiles; adverse effects.\n\nSample Size: 332 patients (166 per group), non-inferiority margin 10 percentage points, one-sided alpha 0.025, 80% power, estimated baseline event rate 10%, with 15% dropout allowance.",[29,30,31,32],"Postpartum Hemorrhage","Uterine Atony","Cesarean Section","Blood Loss, Surgical",[34,35,36,37,38,39,40,41,42],"Carbetocin","Oxytocin","Uterotonic","Elective Cesarean Delivery","Non-Inferiority Trial","Uterine Tone","Gravimetric Blood Loss","Obstetric Anesthesia","Spinal Anesthesia","NOT_YET_RECRUITING","2026-06-04",{"date":46,"type":47},"2026-06-09","ACTUAL",{"date":49,"type":23},"2026-08",{"date":51,"type":23},"2028-08",{"name":53,"class":54},"Mansoura University","OTHER",1,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100638930","exteriorization-versus-in-situ-hysterotomy-repair-during-cesarean-effects-on-uterine-tone-100638930","NCT07606846","Exteriorization Versus In Situ Hysterotomy Repair During Cesarean: Effects on Uterine Tone","Uterine Exteriorization Versus In Situ Hysterectomy Repair During Cesarean Delivery: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-55\n* Undergoing cesarean section\n\nExclusion Criteria:\n\n* Patient age \\\u003C18 or \\>55\n* Case urgency deemed too great for consent","55 Years",{"count":65,"type":23},60,[67],"NA","During standard cesarean deliveries, there are two ways that obstetricians repair the incision on the uterus (hysterotomy after delivery of the baby. One method involves lifting the uterus out of its regular place in the abdomen to repair the incision (uterine exteriorization for repair). The second method involves leaving the uterus inside the abdomen to repair the uterus (in situ repair). Both of these methods are regularly used by obstetricians during cesarean deliveries, and it is not currently known if one has benefits over the other. Currently, surgeons use both methods, but lifting the uterus out of its place is slightly more common. In this study, participants will be randomly assigned to have one of these techniques performed during their surgery. Researchers will be investigating whether one technique or the other leads to better contraction of the uterus after delivery, less bleeding, less intra-operative nausea\u002Fvomiting, or a better patient experience than another.",[29,30,70,31],"Uterine Atony With Hemorrhage",[29,30,72,31,73,39],"Uterine Atony with Hemorrhage","Cesarean Delivery","2026-05-22",{"date":76,"type":47},"2026-05-27",{"date":78,"type":23},"2026-06-01",{"date":80,"type":23},"2029-06-01",{"name":82,"class":54},"Stanford University",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":24,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100640535","balloon-tamponade-versus-gauze-packing-for-postpartum-hemorrhage-100640535","NCT07609589","Balloon Tamponade Versus Gauze Packing for Postpartum Hemorrhage","Comparison of Efficacy of Uterine Balloon Tamponade Versus Uterine Gauze Packing in Patients With Postpartum Hemorrhage With Uterine Atony","Inclusion Criteria:\n\n* Women aged 18 to 40 years\n* Gestational age between 37 and 42 weeks\n* Parity up to 4\n* Diagnosed with postpartum hemorrhage due to uterine atony\n\nExclusion Criteria:\n\n* Postpartum hemorrhage due to perineal, cervical, or vaginal trauma\n* Retained products of conception\n* Vaginal delivery after previous cesarean section\n* Known coagulation disorders\n* Sepsis","40 Years",{"count":92,"type":23},216,[67],"Postpartum hemorrhage due to uterine atony is a major cause of maternal morbidity and mortality. This randomized controlled trial aims to compare the efficacy of uterine balloon tamponade and uterine gauze packing in controlling bleeding in women with postpartum hemorrhage. A total of 216 participants will be randomly assigned to one of the two treatment groups. All patients will receive standard medical management including uterotonic agents prior to intervention. The primary outcome is cessation of uterine bleeding within 24 hours after the procedure. This study aims to identify a safe and effective method for managing postpartum hemorrhage in a resource-limited setting.",[29,30],[97,98,99,100],"postpartum hemorrhage","uterine atony","balloon tamponade","uterine packing","2026-05-21",{"date":76,"type":47},{"date":104,"type":23},"2026-07-01",{"date":106,"type":23},"2027-01-10",{"name":108,"class":54},"Khyber Teaching Hospital",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":55},"100623814","phase-4-carbetocin-uterotonic-treatment-in-twin-pregnancies-for-prevention-of-postpartum-hemorrhage-100623814","NCT07401524","Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage","Carbetocin Administration for the Prevention of Postpartum Hemorrhage in Twin Deliveries: A Randomized Controlled Trial","CUTT-PPH","Inclusion Criteria:\n\n* Pregnant individuals aged ≥18 years\n* Twin pregnancies\n* Gestational age ≥23 weeks\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to carbetocin\n* Higher-order multiple gestation (triplets or more)\n* Maternal age \\\u003C18 years\n* Known placenta accreta spectrum\n* Known bleeding disorder\n* Intrauterine fetal death of one or more fetuses\n* Hyponatremia precluding oxytocin use\n* Planned delivery at a non-participating hospital",{"count":118,"type":23},120,[26],"The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems.\n\nIn this study, bleeding will be evaluated by measuring how much blood hemoglobin levels drop from before delivery to the day after delivery.\n\nThe main questions this study aims to answer are:\n\n* Does giving carbetocin after delivery lower blood loss compared with standard oxytocin treatment?\n* Is carbetocin safe and practical to use in twin deliveries?\n\nResearchers will compare carbetocin to standard oxytocin treatment to see which approach better prevents bleeding after twin vaginal or cesarean delivery.\n\nParticipants will:\n\n* Be randomly assigned to receive either carbetocin or standard oxytocin after the second twin is delivered\n* Have blood tests before delivery and on the day after delivery\n* Be followed during their hospital stay and for up to six weeks after delivery for safety outcomes",[29,122],"Twin Pregnancy",[34,35,124,29],"Twin Delivery","RECRUITING","2026-05-05",{"date":128,"type":47},"2026-05-08",{"date":126,"type":47},{"date":131,"type":23},"2028-12-01",{"name":133,"class":134},"Sheba Medical Center","OTHER_GOV",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100553123","phase-4-swift---swiss-factor-xiii-trial-in-pph-100553123","NCT06481995","SWIFT - SWIss Factor XIII Trial in PPH","Early Factor XIII Replacement in Postpartum Hemorrhage: Multi-center, Randomized, Controlled, Investigator-initiated Trial","SWIFT","Inclusion Criteria:\n\n* planned vaginal delivery\n* singleton vital pregnancy\n* gestational age at delivery \\>= 30+0 weeks\n* maternal weight at admission for delivery \\\u003C100 kg\n\nExclusion Criteria:\n\n* Antithrombotic therapy in pregnancy (therapeutic dosage) until admission for delivery (LMWH, UFH)\n* diagnosis of preeclampsia (ISSHP classification , eclampsia or HELLP syndrome),\n* known history of deep vein thrombosis or pulmonary embolism,\n* known diagnosis of bleeding disorder or thrombophilia,\n* known thrombocytopenia during second half of pregnancy with thrombocytes \\\u003C 100 G\u002FL,\n* known anemia during second half of pregnancy with Hb\\\u003C80 g\u002FL,\n* known sickle cell disease,\n* known malignant tumor(s),\n* participation in another study with investigational drug within the 30 days preceding and during the present study,\n* inability to follow the procedures of the study, e.g. due to language problems,\n* known or suspected non-compliance, drug or alcohol abuse.\n\nExclusion criteria prior randomization\n\n* Maternal fever ≥39.0°C\n* unplanned cesarean delivery is performed,\n* Measured Blood Loss remains \\\u003C 700 mL after administration of 1g tranexamic acid .\n* Postpartum hemorrhage due to occult bleeding (intra-abdominal, retroperitoneal, parametric),",{"count":144,"type":23},988,[26],"The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH).\n\nSummary of current body of evidence:\n\n* Morbidity and mortality due to PPH is rising.\n* Current guidelines focus on replenishment of fibrinogen as an initial step in the treatment of PPH-related coagulopathy, despite non-conclusive evidence in all prospective trials.\n* Trials from other specialties demonstrate a significant impact of FXIII on perioperative bleeding complications; a previous study at the University Hospital Zurich showed that pre-partum factor XIII activity had a strong association to postpartum blood loss.\n\nTherefore, this nationwide, multi-center, randomized, controlled trial in multiple perinatal centers across Switzerland will be conducted. The goal is to determine if postpartum blood loss and PPH-related complications can be reduced by replenishing FXIII.\n\nAll participating women receive, according to the national guideline, 1g tranexamic acid (TXA) i.v. in case of PPH (measured blood loss \\[MBL\\] ≥ 500 mL) during the pre-study phase. Randomization takes place if bleeding continues and exceeds 700mL. The intervention group then receives FXIII (Fibrogammin®) according to approved dosage in addition to obstetric standard of care treatment for causes of PPH; the control group receives only standard of care treatment.",[29,148,149,150,151],"Coagulation Disorder","Coagulation Factor Deficiency","Hemorrhage","Postpartum Complication",[153,154],"Postpartum hemorrhage","coagulation factor XIII","2026-04-21",{"date":157,"type":47},"2026-04-27",{"date":159,"type":47},"2024-07-09",{"date":161,"type":23},"2028-12-31",{"name":163,"class":54},"Christian Haslinger",9,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":173,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":55},"100632866","effect-of-simulation-based-postpartum-hemorrhage-training-on-team-performance-in-senior-anesthesiology-teams-100632866","NCT07519252","Effect of Simulation-Based Postpartum Hemorrhage Training on Team Performance in Senior Anesthesiology Teams","A Prospective Interventional Study Evaluating the Effect of Simulation-Based Postpartum Hemorrhage Training on Team Performance and Crisis Resource Management Skills Among Senior Anesthesiology Residents","PPH-SIM","Inclusion Criteria:\n\n* Senior anesthesiology residents\n* Currently working in the department of anesthesiology and reanimation\n* Voluntary participation in the study\n\nExclusion Criteria:\n\n* Refusal to participate\n* Incomplete participation in the simulation session",true,"ALL","24 Years",{"count":177,"type":23},36,[67],"This prospective interventional study aims to evaluate the effect of simulation-based postpartum hemorrhage (PPH) training on team performance and crisis resource management skills among senior anesthesiology residents. Participants will undergo a structured high-fidelity simulation training program focused on postpartum hemorrhage management. Performance will be assessed before and after the intervention using validated assessment tools, including crisis resource management scoring systems. The study seeks to determine whether simulation-based training improves clinical decision-making, team communication, and overall performance in obstetric emergencies.",[29,181],"Simulation Based Medical Education",[29,181,183,184,185,186,187],"Anesthesiology Education","Crisis Resource Management","Team Performance","Obstetric Emergencies","Resident Training","2026-04-13",{"date":190,"type":47},"2026-04-16",{"date":192,"type":23},"2026-05",{"date":194,"type":23},"2026-10",{"name":196,"class":54},"Mehmet Kırıköz",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":24,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":55},"100593354","thumb-multi-centre-cluster-trial-for-caesarean-section-haemorrhage-100593354","NCT07005349","THUMB: Multi-centre Cluster Trial for Caesarean Section Haemorrhage","Rule of THUMB: A Multi-centre Cluster Trial Evaluating the Implementation of a Perioperative Care Complex Intervention to Improve Outcomes From Haemorrhage During and After Caesarean Section in African Hospitals","Inclusion Criteria:\n\n* Any patient who requires a caesarean section in participating countries with hospitals that routinely perform caesarean section.\n\nExclusion Criteria:\n\n* Patients who opt out of the trial will be excluded.",{"count":205,"type":23},2400,[67],"The quality improvement project evaluating the delivery of a perioperative care complex intervention to improve haemorrhage-related outcomes in patients undergoing caesarean section. The objectives of the current study will be:\n\n1. To evaluate whether implementation of the 'Rule of THUMB' perioperative complex intervention increases risk assessment, diagnosis and compliance with proven interventions for haemorrhage during and after caesarean section.\n2. To understand the influence of contextual and socio-dynamic factors on how the trial results were achieved and how the intervention mechanisms did, or did not, work in practice (the process evaluation). The findings from this study will be used subsequently to modify and improve the quality improvement intervention, so that it can be delivered at scale across Africa and assess its impact on haemorrhage during and after caesarean section in the future.",[29],"2026-04-08",{"date":188,"type":47},{"date":212,"type":47},"2025-06-01",{"date":214,"type":23},"2026-06-30",{"name":216,"class":54},"Bruce Biccard",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":223,"targetDuration":4,"studyType":24,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":55},"100538021","comparing-the-dose-response-profiles-of-uterotonics-after-initial-carbetocin-administration---an-ex-vivo-study-in-desensitized-human-myometrium-100538021","NCT06285409","Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium","Inclusion criteria\n\n* Patients who give written consent to participate in this study\n* Patients with gestational age 37-41 weeks\n* Non-laboring patients, not exposed to exogenous oxytocin\n* Patients requiring elective primary or first repeat CD\n* Patients undergoing CD under spinal anesthesia\n\nExclusion criteria\n\n* Patient refusal\n* Patients who require general anesthesia\n* Patients in labour and those receiving oxytocin for induction of labour\n* Emergency CD\n* placenta accreta spectrum disorder\n* Patients who have had previous uterine surgery or \\>1 previous CD\n* Patients with any condition predisposing to uterine atony and PPH (BMI \\> 40 kg\u002Fm2,\n* Patients on medications that could affect myometrial contractility, such as insulin, nifedipine, labetalol or magnesium sulphate.",{"count":224,"type":23},32,[67],"This study will investigate the effects of drugs called \"uterotonics\" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery. An uncontracted uterine state is called \"uterine atony\", which can lead to an excessive amount of post-delivery bleeding. Carbetocin is an uterotonic drug that works well to prevent post-delivery bleeding. In some cases, carbetocin is not enough to contract the uterus, and ongoing bleeding continues. When that happens, there are other uterotonic medications that can be used. In this study, we aim to find which uterotonic drug, amongst those available (oxytocin, carbetocin, ergometrine or carboprost), is more effective to lower the risk of post-delivery bleeding once carbetocin has already been administered.\n\nThis study will be done by using a very small sample of uterine tissue, taken from the incision site, following delivery by cesarean section. The sample is taken to the laboratory and will be exposed to carbetocin followed by other uterotonic drugs. The information obtained from this study will help modify the treatment for uterine atony and post-delivery bleeding to lower the risk further.",[29],[229,230,231,232],"carbetocin","duratocin","oxytocin","uterine contraction","2026-03-31",{"date":235,"type":47},"2026-04-06",{"date":237,"type":47},"2024-04-04",{"date":239,"type":23},"2026-12",{"name":241,"class":54},"Samuel Lunenfeld Research Institute, Mount Sinai Hospital",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":173,"sex":18,"minAge":248,"maxAge":20,"enrollmentInfo":249,"targetDuration":4,"studyType":24,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":55},"100538020","effect-of-ephedrine-phenylepinephrine-and-norepinephrine-on-myometrial-contractility-in-pregnant-people-with-type-ii-and-gestational-diabetes-during-cesarean-section-an-in-vitro-study-100538020","NCT06285396","Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study","Inclusion Criteria:\n\n* Patients who have given consent to participate in the study\n* Patients with gestational age 37-41 weeks\n* Patients previously diagnosed with either Type II or Gestational diabetes. For the healthy control group, no previous diagnosis is required for inclusion\n* Patients of 19-45 years\n* Patients of normal BMI (18-30 BMI) for the healthy control group only\n* Baby is registered as normal weight for size for the healthy control group only\n* Non-laboring patients, not exposed to exogenous oxytocin\n* Patients requiring elective primary or first repeat caesarean delivery\n* Patients undergoing caesarean delivery under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients who refuse to give written informed consent\n* Patients who require general anesthesia\n* Patients in labor and those receiving oxytocin for induction of labor\n* Emergency caesarean delivery in labor\n* Patients who have had previous uterine surgery involving myometrial dissection or \\>1 previous caesarean delivery\n* Patients with risk factors for PPH such as those with polyhydramnios, preeclampsia, multiple gestation, morbid obesity, macrosomia (large for size baby), and previous history of PPH. However, for diabetic group, those with morbid obesity and macrosomia will not be excluded as these conditions are almost always associated with diabetes.\n* For the healthy control group only, a BMI \\>30 or \\\u003C18\n* Maternal age \\>45","19 Years",{"count":250,"type":23},96,[67],"The goal of this study is to learn about how medication that is used to help treat low blood pressure during a Cesarean delivery (CD) can cause changes to the uterine muscle tissue and its ability to contract, in patients with Type II and gestational diabetes.\n\nSpinal anesthesia administered during elective CD has been known to cause hypotension (low blood pressure) as a side effect during the procedure, and is prevented by administration of vasopressors (medication to raise blood pressure) by the anesthesiologist after the delivery of the baby. Vasopressors treat hypotension by interacting with receptors on blood vessels that increase blood pressure, which can also cause changes to uterine contractility. Inadequate uterine contraction after CD can expose mothers to postpartum hemorrhage (PPH), with diabetic patients displaying a 2.5-times higher risk of PPH.\n\nIt is important to understand how vasopressor(s) might affect the uterine contractility of women with Type II and gestational diabetes. Since medication to contract the uterus is also routinely administered at delivery, it is important to study the effect of these drugs in combination. The purpose of this study is to compare uterine contractility patterns and receptor distribution in women with type II and gestational diabetic and control term pregnant patients with administration of vasopressors. This will be done using small uterine tissue samples taken from the incision site following CD, which will then be used for experiments in the laboratory.",[29],[231,255,256,232],"type II diabetes","gestational diabetes",{"date":235,"type":47},{"date":259,"type":47},"2024-03-18",{"date":239,"type":23},{"name":241,"class":54},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":24,"phases":271,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":55},"100461551","oxytocin-maintenance-infusion-in-labouring-women-undergoing-cesarean-delivery-an-up-down-sequential-allocation-study-100461551","NCT05290129","Oxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study","Inclusion Criteria:\n\n• All patients with induced or augmented labour undergoing cesarean delivery under neuraxial anesthesia (at least 3 hours of prior exposure to oxytocin during labour)\n\nExclusion Criteria:\n\n* All patients who refuse to give written informed consent\n* All patients who declare allergy or hypersensitivity to oxytocin\n* A history of hypertension and\u002For severe cardiac disease(s)\n* All patients who have contraindications for neuraxial anesthesia\n* All patients who will be converted to general anesthesia intraoperatively\n* All patients with placenta previa and multiple gestation","50 Years",{"count":270,"type":23},40,[67],"This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient.\n\nThe investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU\u002Fmin (44 IU\u002Fh), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.",[29],[275,231,276,277,278],"Cesarean delivery","uterotonic","pregnancy","labour",{"date":235,"type":47},{"date":281,"type":47},"2022-08-17",{"date":239,"type":23},{"name":241,"class":54},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":24,"phases":295,"briefSummary":296,"conditions":297,"keywords":298,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100623786","umbilical-cord-drainage-to-prevent-postpartum-hemorrhage-100623786","NCT07401160","Umbilical Cord Drainage to Prevent Postpartum Hemorrhage","Relationship Between Umbilical Cord Drainage and Postpartum Hemorrhage: A Randomized Single-Blind Clinical Trial.","CORD-PPH","Inclusion Criteria:\n\n* Pregnant women aged 18-49 years.\n* Singleton pregnancy.\n* Gestational age ≥37 weeks.\n* active labor with cephalic presentation.\n* Planned for vaginal delivery.\n* Capable of providing informed consent.\n\nExclusion Criteria:\n\n* Planned or emergent cesarean section.\n* Instrumental delivery (e.g., forceps, vacuum).\n* Antepartum hemorrhage.\n* Severe anemia (Hemoglobin \\\u003C8 g\u002FdL) or specific hematological disorders (e.g., sickle cell disease, thalassemia, hemophilia, thrombocytopenia \\\u003C100,000\u002FµL).\n* Use of anticoagulant medication.\n* Non-cephalic fetal presentation (e.g., breech, transverse).\n* Refusal to participate or inability to provide informed consent.","49 Years",{"count":294,"type":23},400,[67],"This study aims to analyze whether there is a significant difference in the occurrence of postpartum hemorrhage between women who underwent umbilical cord drainage and those who did not. Variables such as estimated blood loss volume, drop in hemoglobin levels, and the need for additional maneuvers or treatments to control hemorrhage will be examined. The research will be conducted under a parallel-group clinical trial design at the Hospital Escuela Universitario. Post-birth umbilical cord drainage may contribute to a lower frequency of postpartum hemorrhage compared to not performing it.",[29],[299,300,301,302],"Cord Drainage","Third Stage of Labor","Obstetric Hemorrhage","Labor Stage","2026-02-10",{"date":305,"type":47},"2026-02-13",{"date":307,"type":23},"2026-02-15",{"date":309,"type":23},"2026-09-30",{"name":311,"class":54},"Universidad Nacional Autonoma de Honduras",2,{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":4},"100620104","carbetocin-vs-misoprostol-for-postpartum-hemorrhage-prevention-100620104","NCT07353281","Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention","Carbetocin Versus Misoprostol for the Prevention of Postpartum Hemorrhage After Vaginal Delivery in Women With Risk Factors: A Prospective Randomized Study","Inclusion Criteria\n\n* Women aged 18 years or older\n* Singleton pregnancy\n* Gestational age 37-42 weeks\n* Cephalic presentation\n* Vaginal delivery\n* Presence of one or more risk factors for postpartum hemorrhage, including:\n* Grand multiparity (≥5 previous deliveries)\n* History of postpartum hemorrhage\n* History of manual removal of placenta\n* Estimated fetal weight ≥4,000 grams\n* Polyhydramnios\n* Chorioamnionitis\n* Prolonged oxytocin use during labor (third augmentation cycle or more)\n* Eligible for prophylactic uterotonic therapy after delivery\n* Provided written informed consent\n\nExclusion Criteria\n\n* Multiple gestation\n* Known major fetal anomalies\n* Intrauterine fetal demise (IUFD)\n* Contraindication to vaginal delivery\n* Known hypersensitivity to carbetocin, misoprostol, or oxytocin\n* Known coagulation disorders requiring alternative management\n* Planned cesarean delivery\n* Participation in another interventional study that may affect postpartum bleeding outcomes",{"count":321,"type":23},146,[67],"Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide, particularly among women with known risk factors. Uterotonic agents are routinely administered after vaginal delivery to prevent excessive bleeding. Carbetocin, a long-acting oxytocin analogue, and misoprostol are both used for this purpose, but comparative data in high-risk vaginal deliveries remain limited.\n\nThis prospective randomized study aims to compare the effectiveness and safety of intravenous carbetocin versus rectal misoprostol for the prevention of postpartum hemorrhage in women with risk factors undergoing vaginal delivery at Galilee Medical Center. The primary outcome is the incidence of postpartum hemorrhage. Secondary outcomes include the need for additional uterotonic agents or surgical interventions, changes in hemoglobin levels, blood transfusion requirements, and maternal adverse effects.",[151,29],[326],"Postpartum hemorrhage, Carbetocin, Misoprostol, Vaginal delivery, Uterotonic agents, High-risk pregnancy","2026-01-13",{"date":329,"type":47},"2026-01-20",{"date":331,"type":23},"2026-01-31",{"date":333,"type":23},"2028-01-01",{"name":335,"class":134},"Western Galilee Hospital-Nahariya",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":345,"phases":4,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":55},"100614318","trends-in-the-administration-of-tranexamic-acid-for-postpartum-hemorrhage-100614318","NCT07278037","Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage","A Retrospective Analysis of the Longitudinal Pattern of Tranexamic Acid Administration in Parturients Undergoing Cesarean Delivery Complicated by Postpartum Hemorrhage","Inclusion Criteria:\n\n* 1\\. Patients underwent cesarean delivery with primary postpartum hemorrhage\n\nExclusion Criteria:\n\n1. Gestational age at less than 24 weeks\n2. Absence of the anesthetic record\n3. Received tranexamic acid in the antepartum period\n4. Blood loss less than 1,000 ml",{"count":344,"type":23},648,"OBSERVATIONAL","Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.",[29,348,349,350],"Delivery Complication","Cesarean Section Complications","Perinatal Problems",[352,353,97,354],"cesarean delivery","complications","tranexamic acid","2025-12-16",{"date":357,"type":47},"2025-12-22",{"date":359,"type":47},"2025-12-01",{"date":309,"type":23},{"name":362,"class":54},"Mahidol University",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":24,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":55},"100614434","the-effect-of-placental-cord-drainage-on-the-third-stage-of-labor-and-the-amount-of-postpartum-bleeding-100614434","NCT07279545","The Effect of Placental Cord Drainage on the Third Stage of Labor and the Amount of Postpartum Bleeding","Inclusion Criteria:\n\n* No problem speaking and understanding Turkish\n* Low-risk pregnant women\n* Vertex presentation\n* 37-41st weeks of gestation\n* There are no complications in the mother or the baby that prevent normal birth.\n* The VAS score for the pain felt by the pregnant woman at the time of admission to the study must be less than 3 (to show that the pregnant women were accepted into the study at a time when their pain was at its lowest and their decision-making ability was at a relatively good level)\n\nExclusion Criteria:\n\n* History of postpartum hemorrhage\n* History of postpartum hemorrhage in mother or sister\n* Birth interval less than 2 years\n* Anticoagulant use during pregnancy\n* Smoking during pregnancy\n* Those with low Hb values (Hb\\\u003C11gr\u002FdL)\n* Hematocrit \\\u003C30","35 Years",{"count":371,"type":23},80,[67],"The aim of the study was to evaluate the effect of controlled placental cord drainage by opening the clamp at the maternal end after the umbilical cord is cut during birth on the duration of the third stage of labor (departure of the placenta), the amount of blood loss in the third stage, the amount of bleeding in the 2nd hour postpartum, and the development of postpartum complications.",[29],[376,377,378,97],"active management","third stage of labor","placental cord drainage","2025-12-09",{"date":381,"type":47},"2025-12-12",{"date":383,"type":47},"2025-11-17",{"date":104,"type":23},{"name":386,"class":54},"Saglik Bilimleri Universitesi Gulhane Tip Fakultesi",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":173,"sex":174,"minAge":4,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":55},"100610591","the-effectiveness-of-serious-game-based-training-for-nursing-students-in-postpartum-haemorrhage-management-100610591","NCT07229573","The Effectiveness of Serious Game-Based Training for Nursing Students in Postpartum Haemorrhage Management","The Effectiveness of Serious Game-Based Training for Nursing Students in Postpartum Haemorrhage Management: A Randomised Controlled Trial","Inclusion Criteria:\n\na) Third-year nursing students taking the Obstetrics and Gynaecology Nursing course, b) Not experiencing any verbal or written communication problems, c) Not being an exchange student, d) Being willing to provide written consent before participating in the study.\n\nExclusion Criteria:\n\nNot meeting the inclusion criteria",{"count":395,"type":23},70,[67],"This randomised controlled trial aims to evaluate the effectiveness of serious game-based training for postpartum haemorrhage (PPH) management among third-year nursing students. The study employs a pre-test-post-test design with two parallel groups: an experimental group (game-based education) and a control group (traditional education). The sample size was determined by power analysis to be 70 students in total, with 35 students in each group. Participants will be assigned in a 1:1 ratio by computer-assisted block randomisation by a person independent of the research team; students and instructors will not be blinded, but the biostatistician performing the data analysis will be blinded. The intervention group will first receive traditional education, followed by gamification-based education including nursing interventions in the management of PPB; the control group will receive only traditional education. Data will be collected using the PPK Management Knowledge and Skills Assessment Form and the PPK Management Self-Confidence Scale.",[399,400,401,402,29,403],"Gamification","Gamification in Health Education","Nurse Education","Nursing Students","Nursing Care","2025-11-13",{"date":383,"type":47},{"date":407,"type":47},"2025-11-05",{"date":409,"type":23},"2025-12-30",{"name":411,"class":54},"Sakarya University",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":268,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":424,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":55},"100595628","temporary-aortic-compression-with-the-abdominal-tourniquet-for-refractory-postpartum-hemorrhage-100595628","NCT07034924","Temporary Aortic Compression With the Abdominal Tourniquet for Refractory Postpartum Hemorrhage","ACT-PPH","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical diagnosis of postpartum hemorrhage (PPH) refractory to uterotonics and intrauterine balloon tamponade\n* Estimated blood loss greater than 1300 mL\n* Oral informed consent provided prior to device application\n\nExclusion Criteria:\n\n* Patients with postpartum bleeding as a result of trauma, retained placenta or coagulopathy were excluded",{"count":420,"type":23},20,[67],"This multicenter study aims to evaluate effectiveness and safety of using the AAJT-S device as a temporary intervention for severe, atony-related PPH that is refractory to standard therapies",[29],[97],"2025-10-02",{"date":427,"type":47},"2025-10-07",{"date":429,"type":47},"2025-07-01",{"date":431,"type":23},"2026-07",{"name":433,"class":434},"LLC UkrMedGroup","INDUSTRY",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":442,"targetDuration":4,"studyType":24,"phases":444,"briefSummary":445,"conditions":446,"keywords":447,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":4},"100607411","rectal-misoprostol-for-reducing-blood-loss-in-elective-cesarean-section-100607411","NCT07188207","Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section","The Efficacy of Adding Preoperative Rectal Misoprostol for Decreasing Intraoperative and Postoperative Blood Loss at Elective Cesarean Section","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Singleton pregnancy at ≥37 weeks of gestation.\n* Elective cesarean section planned under spinal anesthesia.\n* Hemodynamically stable prior to surgery.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Multiple pregnancy.\n* Antepartum hemorrhage (e.g., placenta previa, abruption).\n* Coagulopathy, thrombocytopenia, or anticoagulant therapy.\n* Severe medical comorbidities (e.g., uncontrolled hypertension, cardiac disease, hepatic or renal impairment).\n* Known allergy or contraindication to prostaglandins or oxytocin.\n* Intrauterine fetal death or major fetal anomaly.\n* Refusal to participate.",{"count":443,"type":23},282,[67],"This randomized controlled trial aims to evaluate the efficacy of adding preoperative rectal misoprostol to standard oxytocin for reducing intraoperative and postoperative blood loss in women undergoing elective cesarean section. Misoprostol is a prostaglandin E1 analogue that is inexpensive, heat-stable, and effective as a uterotonic agent. The study will compare outcomes between two groups: women receiving oxytocin alone and women receiving oxytocin plus rectal misoprostol. The primary outcome is the reduction of blood loss during and after surgery. Secondary outcomes include changes in hemoglobin levels, need for additional uterotonics, maternal safety, and overall recovery.",[29],[448,35,73],"Misoprostol","2025-09-20",{"date":451,"type":47},"2025-09-23",{"date":453,"type":23},"2025-10-01",{"date":455,"type":23},"2026-12-31",{"name":457,"class":54},"Assiut University",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":345,"phases":4,"briefSummary":468,"conditions":469,"keywords":477,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":55},"100599361","non-invasive-detection-of-iron-deficiency-in-obstetrics-100599361","NCT07083492","Non-invasive Detection of Iron Deficiency in Obstetrics","Point-of-care Transcutaneous Longitudinal Non-invasive Detection of Iron Deficiency in Obstetrics (PICCOLINO-Trial)","PICCOLINO","Inclusion Criteria:\n\n* any timepoint during or up to 3 months after pregnancy\n* age ≥ 18 years\n* written informed consent\n\nExclusion Criteria:\n\n* previous participation in this study\n* refusal of blood sampling\n* incapacity to give informed consent",{"count":467,"type":23},500,"Validation of non-invasive measurement of zinc protoporphyrin for detection of iron deficiency in pregnancy.\n\nIn addition, the impact of iron deficiency on the incidence of postpartum depression, restless legs syndrome, obstetric complications and quality of life will be examined.",[470,471,472,473,29,474,475,476],"Iron Deficiency Anemia of Pregnancy","Iron-deficiency","Restless Leg Syndrome in Pregnancy","Restless Leg Syndrome Due to Iron Deficiency Anaemia","Postpartum Depression","Pregnancy Anemia","Iron Deficiency (Without Anemia)",[478,479,480,481],"Zinc protoporphyrin","Non-invasive detection","Obstetric anesthesia","Patient blood management","2025-07-23",{"date":484,"type":47},"2025-07-24",{"date":486,"type":47},"2022-11-15",{"date":455,"type":23},{"name":489,"class":54},"Wuerzburg University Hospital",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":24,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100592698","intrauterine-balloon-bakri-versus-uterine-tamponade-with-chitosan-gauze-celox-pph-in-the-management-of-postpartum-hemorrhage-refractory-to-medical-treatmen-100592698","NCT06996808","Intrauterine Balloon (Bakri©) Versus Uterine Tamponade With Chitosan Gauze (Celox PPH©) in the Management of Postpartum Hemorrhage Refractory to Medical Treatmen","Intrauterine Balloon (Bakri©) Versus Uterine Tamponade With Chitosan Gauze (Celox PPH©) in the Management of Postpartum Hemorrhage Refractory to Medical Treatment: A Multicenter Randomized Controlled Trial","Inclusion Criteria: Participants must meet all of the following criteria to be eligible for inclusion:\n\n* Women aged 18 years or older who have delivered either vaginally or via cesarean section.\n* Diagnosis of postpartum hemorrhage, defined as an estimated blood loss (EBL) greater than 1000 mL within the first 24 hours postpartum.\n* Refractory to first-line medical therapy, specifically high-dose oxytocin (≥40 IU total administered intravenously or intramuscularly), a full dose of methylergometrine (0.2 mg IM or IV), and administration of tranexamic acid (1 g IV).\n* Hemodynamically stable at the time of enrollment, allowing time for the application of a mechanical or topical intervention.\n\nExclusion Criteria: Patients will be excluded if they meet any of the following conditions:\n\n* Clinical or radiological suspicion of placenta accreta spectrum (PAS), including placenta increta or percreta, which may necessitate immediate surgical management.\n* Known pre-existing or newly diagnosed coagulopathy, including but not limited to thrombocytopenia (\\\u003C50,000\u002FμL), von Willebrand disease, hemophilia, or disseminated intravascular coagulation (DIC), which may compromise the safety or efficacy of the interventions.\n* Hemodynamic instability defined by persistent hypotension (systolic BP \\\u003C90 mmHg or MAP \\\u003C65 mmHg) despite resuscitation, or active decision to proceed to surgical intervention (e.g., laparotomy, uterine artery embolization, or hysterectomy) without delay.",{"count":498,"type":23},196,[67],"Postpartum hemorrhage (PPH) remains one of the leading causes of maternal morbidity and mortality worldwide, particularly in low- and middle-income countries. It is defined as blood loss of more than 500 mL after vaginal delivery or more than 1000 mL after cesarean section, but severe PPH is typically identified when blood loss exceeds 1000 mL regardless of delivery mode. The initial management of PPH includes the administration of uterotonics such as oxytocin, methylergometrine, and tranexamic acid. However, a subset of patients remains unresponsive to medical therapy, necessitating second-line interventions to avoid escalation to invasive procedures such as uterine artery embolization or peripartum hysterectomy.\n\nAn intrauterine balloon tamponade device (Bakri©), is commonly used as a mechanical method to control uterine bleeding by exerting direct pressure on the uterine walls. Its use has been widely adopted and incorporated into international guidelines due to its relative ease of use and safety profile. Despite its effectiveness, the failure rate of Bakri balloon placement can range from 20% to 40%, especially in cases of coagulopathy or diffuse atony.\n\nGauzes with a chitosan-based hemostatic dressing (Celox PPH ©) , has been extensively used in trauma settings and is increasingly being explored for surgical and obstetric applications. Its mechanism involves promoting clot formation independent of the clotting cascade, making it potentially beneficial in patients with coagulopathies. Preliminary data and case reports suggest that Celox PPH© may be effective in controlling intrauterine bleeding when used as a packing material after vaginal or cesarean delivery, but no high-quality randomized controlled trial has yet compared it directly with standard interventions.\n\nGiven the clinical need for alternative second-line treatments for PPH unresponsive to medical therapy, this study proposes a head-to-head comparison of the Bakri balloon and Celox gauze. The findings will help inform evidence-based guidelines and may offer new strategies to reduce maternal transfusion requirements, prevent hysterectomy, and shorten hospital stays in patients experiencing severe PPH.",[29],"2025-05-30",{"date":504,"type":47},"2025-06-04",{"date":506,"type":23},"2025-09-01",{"date":508,"type":23},"2029-01",{"name":510,"class":54},"University of Roma La Sapienza",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":174,"minAge":19,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":345,"phases":4,"briefSummary":521,"conditions":522,"keywords":527,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":55},"100564929","personalized-viscoelastic-testing-guided-bleeding-management-in-liver-surgery-neurosurgery-and-obstetrics-100564929","NCT06635564","Personalized ViscoElastic Testing-guided Bleeding Management In Liver Surgery, Neurosurgery and Obstetrics","Personalized ViscoElastic Testing-guided Bleeding Management In Liver Surgery, Neurosurgery and Obstetrics - a Prospective Comparison of the Novel ClotPro With ROTEM and TEG","VETILNO","Inclusion Criteria:\n\n1. Vulnerable patient cohorts\n\n   * Patients undergoing elective liver surgery defined as one of the following invasive procedures:\n\n     * Liver resection (anatomic or non-anatomic segmental resection, right or left hepatectomy, right or left extended hepatectomy),\n     * Orthotopic liver transplantation,\n   * Pregnant women undergoing an elective caesarean section, and\n   * Patients undergoing an elective intracranial neurosurgery.\n2. Written informed consent\n\nExclusion Criteria:\n\nnone",{"count":520,"type":23},240,"The ClotPro analyzer is a new generation viscoelastic analyzer for the in vitro assessment of blood coagulation. This study aims to assess the agreement of ClotPro 6.0, ROTEM delta, and TEG 6s in three distinct cohorts: i) patients with liver disease undergoing liver surgery, ii) pregnant women undergoing elective cesarean section, and iii) patients undergoing elective intracranial neurosurgery. Further coagulation tests will be performed (standard laboratory coagulation tests, thrombin and plasmin generation tests) in an exploratory fashion to compare them with viscoelastic test results. The obtained test results will not result in any diagnostic or therapeutic consequences for patients included in this study.",[523,524,29,525,526],"Thrombelastography","Liver Transplant","Bleeding Disorder","Intracranial Hemorrhages",[528,529],"Viscoelastic testing","personalized bleeding management","2025-05-20",{"date":532,"type":47},"2025-05-23",{"date":534,"type":47},"2024-07-01",{"date":536,"type":23},"2026-07-31",{"name":538,"class":54},"Medical University of Vienna",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":55},"100458100","phase-3-double-simultaneous-uterotonic-agents-versus-single-agent-regimen-to-prevent-early-postpartum-hemorrhage-100458100","NCT05245227","Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage","A Randomized Controlled Trial of Double Simultaneous Uterotonic Agents (Misoprostol Plus Intravenous Oxytocin) Versus Single Agent Regimen (Intravenous Oxytocin Only) to Prevent Early Postpartum Hemorrhage","Inclusion Criteria:\n\n\\- All women 18 years and older admitted to delivery at Stony Brook University hospital who agree to participate in the study\n\nExclusion Criteria:\n\n* Women under 18 years old\n* Women with known coagulation disorders\n* Women with planned cesarean hysterectomy\n* Women with known placental accreta spectrum disorders\n* Women with known allergy to prostaglandins",{"count":547,"type":23},1358,[549],"PHASE3","To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage.\n\nThere have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage.\n\nSpecific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage.\n\nSpecific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).",[29],"2025-04-30",{"date":554,"type":47},"2025-05-04",{"date":556,"type":47},"2025-01-27",{"date":558,"type":23},"2027-01-01",{"name":560,"class":54},"Stony Brook University",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":268,"enrollmentInfo":568,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":55},"100574060","phase-4-prophylactic-tranexamic-acid-reduces-postpartum-hemorrhage-100574060","NCT06754371","Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage","Safety and Efficacy of Prophylactic Tranexamic Acid in Reducing Postpartum Hemorrhage After Cesarean Delivery in Women with Systemic Autoimmune Disease：A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing cesarean delivery\n2. Preoperative diagnosis of pregnancy with systemic autoimmune diseases (systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjogren's syndrome, rheumatoid arthritis, undifferentiated connective tissue disease)\n3. Obtain informed consent.\n\nExclusion Criteria:\n\n1. intrauterine fetal death\n2. Existing\u002Fprevious history of thromboembolism\n3. Hemorrhagic disease, significant prenatal bleeding\n4. Balloon placement of internal iliac artery\n5. Allergic to tranexamic acid\n6. Severe renal insufficiency (serum creatinine \\>451μmol\u002FL or blood urea nitrogen \\>20mmol\u002FL)\n7. Epilepsy",{"count":569,"type":23},276,[26],"Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including PPH, preeclampsia, thromboembolism, abortion, and intrauterine growth restriction. The incidence of PPH in women with systemic lupus erythematosus has been reported to be as high as 34%. Prevention of PPH is the key to reduce complications in high-risk women. In recent years, a large number of clinical studies have confirmed that the early preventive use of tranexamic acid(TXA) can reduce the amount of blood loss, the need for additional uterine contraction agents, the risk of blood transfusion, and maternal adverse outcomes, and do not increase the risk of thromboembolic events, which can be used to prevent PPH. However, the study population of TXA is mainly low-risk puerpera, and there is still a lack of relevant research on TXA used in pregnant women with systemic autoimmune diseases. The purpose of this study was to evaluate the safety and efficacy of TXA in preventing postpartum hemorrhage after cesarean delivery in women with systemic autoimmune disease, as well as the maternal and neonatal risks associated with systemic autoimmune disease, to provide evidence for clinical practice and further research.",[29,573],"Systemic Autoimmune Diseases",[97,575,352,576],"systemic autoimmune disease","thromboembolism","2025-03-13",{"date":579,"type":47},"2025-03-17",{"date":581,"type":47},"2025-01-06",{"date":583,"type":23},"2027-06",{"name":585,"class":54},"RenJi Hospital",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":174,"minAge":4,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":24,"phases":596,"briefSummary":597,"conditions":598,"keywords":601,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":606,"leadSponsor":608,"locationsCount":4},"100583173","the-effect-of-simulation-based-training-on-postpartum-haemorrhage-management-skills-100583173","NCT06872879","The EFFECT of SIMULATION-BASED TRAINING on POSTPARTUM HAEMORRHAGE MANAGEMENT SKILLS","The EFFECT of SIMULATION-BASED TRAINING with TWO DIFFERENT REALITY LEVELS on POSTPARTUM HAEMORRHAGE MANAGEMENT SKILLS in NURSING STUDENTS","(SBT)","Inclusion Criteria:\n\n* Volunteering to participate in the research\n* To have a grade point average of 2.00 and above\n\nExclusion Criteria:\n\n* Not participating in all stages of the training programme\n* Incomplete completion of data collection tools\n* Wanting to leave the research.",{"count":595,"type":23},64,[67],"This study was planned to determine the effect of simulation-based training using two different reality levels-visually enhanced mental simulation (VEMS) and hybrid simulation-on postpartum haemorrhage (PPH) management skills in nursing students.",[599,600,29],"Simulation Training","Nursing",[599,600,29],"2025-03-07",{"date":604,"type":47},"2025-03-12",{"date":579,"type":23},{"date":607,"type":23},"2025-04-24",{"name":609,"class":54},"Bandırma Onyedi Eylül University",{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":55},"100482482","phase-3-tranexamic-acid-to-prevent-heavy-bleeding-after-childbirth-in-women-at-higher-risk-100482482","NCT05562609","Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women At Higher Risk","Tranexamic Acid by the Intramuscular or Intravenous Route for the Prevention of Postpartum Haemorrhage in Women At Increased Risk: a Randomised, Double-blind, Placebo-controlled Trial","I'M-WOMAN","Inclusion Criteria:\n\n* Women aged 18 years or older who are admitted to hospital to give birth vaginally or by caesarean section, who have one or more known risk factors for PPH\n\nExclusion Criteria:\n\n* Women who have a clear indication or contraindication for TXA",{"count":619,"type":23},30000,[549],"Heavy bleeding after childbirth, known as a postpartum haemorrhage (PPH), causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The I'M WOMAN trial is a research study to see whether giving TXA just before childbirth will stop women developing PPH. The trial will assess the effects of intramuscular (IM) and intravenous (IV) tranexamic acid on PPH, side effects and other important maternal health outcomes.",[29],[354,624,625,277,626,627],"postpartum haemorrhage","bleeding","antifibrinolytic","intramuscular",{"date":629,"type":47},"2025-03-11",{"date":631,"type":47},"2024-04-22",{"date":633,"type":23},"2025-09",{"name":635,"class":54},"London School of Hygiene and Tropical Medicine",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":644,"enrollmentInfo":645,"targetDuration":4,"studyType":24,"phases":647,"briefSummary":648,"conditions":649,"keywords":650,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":55},"100385893","phase-3-tranexamic-acid-for-preventing-blood-loss-following-a-cesarean-delivery-in-women-with-placenta-previa-100385893","NCT04304625","TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA","TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA: a Multicenter Randomised, Double Blind Placebo Controlled Trial","TRAAPrevia","Inclusion Criteria:\n\n* Age≥ 18 years\n* Placenta previa defined by a placental edge below 20mm from internal cervical os diagnosed at the most recent transvaginal ultrasound examination before delivery, as per French guidelines\n* Cesarean delivery before or during labor\n* Gestational age at delivery ≥ 32 weeks + 0\n* Affiliated or beneficiary to a health security system\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of venous (deep vein thrombosis and\u002For pulmonary embolism) or arterial (angina pectoris, myocardial infarction, stroke) thrombotic event\n* History of epilepsy or seizure\n* Chronic or acute cardiovascular disease (including foramen oval, mitral stenosis, aortic stenosis, heart transplant, pulmonary hypertension); chronic or acute renal disease (including chronic or acute kidney failure with glomerular filtration rate \\\u003C90 mL\u002Fmin, renal transplantation), chronic active or acute liver disorder with hemorrhagic or thrombotic risk (including cirrhosis, portal hypertension, Budd-Chiari syndrome)\n* Active autoimmune disease with thromboembolic risk (including lupus, antiphospholipid syndrome, Crohn's disease)\n* Sickle cell disease (homozygous)\n* Severe hemostasis disorder prothrombotic (Factor V Leiden mutation - homo or heterozygous; Activated protein C (APC) resistance, Protein C deficiency, Protein S deficiency - aside from pregnancy, Homocysteinemia, , Factor 2 mutation - homo or heterozygous, Deficiency in antithrombin 3), prohemorragic (von Willebrand disease requiring desmopressin treatment during delivery, thrombocytopenia (\\\u003C30000\u002Fmm3), Glanzmann disease, hypofibrinogenemia (\\\u003C1g\u002FL) -aside from pregnancy)\n* High prenatal suspicion of placenta accreta spectrum disorder according to the obstetrician in charge\n* Placenta praevia diagnosed during delivery\n* Abruptio placentae\n* Significant bleeding (estimated blood loss\\>500ml) within 12 hours before cesarean delivery\n* Eclampsia \u002F HELLP syndrome\n* In utero fetal death\n* Administration of low-molecular-weight heparin or antiplatelet agents during the 7 days before delivery\n* Tranexamic acid contraindication\n* Sodium chloride contraindication\n* Women under legal protection\n* Poor understanding of the French language","65 Years",{"count":646,"type":23},1380,[549],"Several randomized, controlled trials, mostly involving women undergoing cesarean delivery, have shown that the prophylactic intravenous administration of 1 g of tranexamic acid after childbirth reduced blood loss. Most were small, single-centre trials with considerable methodologic limitations.\n\nIt is important to emphasize that none of these RCTs has included women at increased risk of PPH such as placenta previa, a context in which the prevalence of moderate and severe blood loss is significantly higher and where the magnitude of the effect of TXA may highly differ compared to low risk women",[29],[153,651,652],"tranexamix acid","placenta previa","2025-02-07",{"date":655,"type":47},"2025-02-10",{"date":657,"type":47},"2020-08-07",{"date":659,"type":23},"2027-09",{"name":661,"class":54},"University Hospital, Bordeaux"]